ASCO 2026: Latest updates in mRCC
Dr Bernadett Szabados (University College London Hospital, London, UK), Dr Yohann Loriot (Gustave Roussy, Paris, France), Prof Andrea Necchi (The Vita-Salute San Raffaele University, Milan, Italy), Dr Cosimo De Nunzio (Sant'Andrea Hospital, University La Sapienza, Rome, Italy) and Dr Felix Guerrero-Ramos (Hospital Universitario 12 de Octubre, Madrid, Spain) discuss bladder cancer highlights from EAU 2024.
The experts focused on the results of the CheckMate 274 and IMvigor011 phase III trials, as discussed by Dr Loriot and Prof Necchi.
They also talked about treatment options for patients in the bacillus Calmette–Guérin (BCG) refractory setting, as well as the data from the SunRISe-1 and BladderGATE trials.
ASCO 2026: Latest updates in mRCC
ASCO GU 2026: Updates in renal cancer
ASCO GU 2026: Updates in localised prostate cancer
Best practice in precision medicine for prostate cancer
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment